United States Patent 6,359,016 landscape: What is protected in dexamethasone/ciprofloxacin aqueous ophthalmic/otic/nasal suspensions?

US 6,359,016 protects a specific topical aqueous suspension formulation intended for the eye, ear, or nose that pairs dexamethasone (as alcohol or acetate) with ciprofloxacin (as hydrochloride monohydrate), within defined pH (4.5 ± 0.2), osmolality (250 to 350 mOsm, with NaCl > 0.3 wt%), and a particular combination of nonionic polymer + nonionic surfactant, plus optional chelating/pH/borate/preservative elements. Independent claims 1–3 set the broad formulation boundaries; dependent claims 4–5 narrow to specific quaternary ammonium halide and chelating agent selections.

What patents protect US 6,359,016 (dexamethasone + ciprofloxacin suspension) in the US?

US 6,359,016 is a composition-of-matter patent covering a suspension (not a solution) for ocular/otic/nasal administration meeting the claim-defined physicochemical specs and ingredient selections.

Claim core (formulation-defining elements)

All independent claims share these required boundaries:

Actives
- Dexamethasone at 0.01–0.5 wt%
- Ciprofloxacin at 0.1–0.4 wt%
Drug forms
- Dexamethasone is selected from dexamethasone alcohol and dexamethasone acetate.
- Ciprofloxacin is ciprofloxacin hydrochloride, monohydrate.
Salt and tonicity
- NaCl amount such that osmolality is ~250–350 mOsm, with NaCl > 0.3 wt%
pH
- pH 4.5 ± 0.2
Excipient system
- Nonionic polymer at 0.1–0.5 wt%
- Nonionic surfactant at 0.01–0.2 wt%
Buffer
- A buffer is required to support pH
Optional components
- preservative; boric acid; pH-adjusting agent; chelating agent

Where the independent claims differ (scope splits)

Claim 1 (general polymer/surfactant constraints): sets the broad polymer and surfactant category constraints without naming specific species.
Claim 2 (specific excipients): locks in
- nonionic polymer = hydroxyethyl cellulose (HEC) at 0.2 wt%
- nonionic surfactant = tyloxapol at 0.05 wt%
Claim 3 (adds cationic antimicrobial + boric acid + chelator boundaries):
- requires quaternary ammonium halide at 0.005–0.3 wt%
- requires chelating agent at 0.001–0.1 wt%
- requires boric acid at 0.1–1.5 wt%
- pH remains 4.5 ± 0.2; includes optional pH-adjusting agent
Claims 4–5 (species narrowing):
- Claim 4: quaternary ammonium halide = polyquaternium-1 or benzalkonium halides; chelator = EDTA salts specified.
- Claim 5: quaternary ammonium halide = benzalkonium chloride and chelator = edetate disodium.

Landscape reality: how this claim set typically functions in freedom-to-operate

In practice, US 6,359,016 behaves like a formulation “gate” patent: a generic or competitor typically avoids infringement by changing at least one required claim element that is not merely “range-tunable.” The most common divergence points are:

change the dexamethasone salt/ester identity (outside alcohol/acetate selection),
change ciprofloxacin salt/hydrate identity (outside hydrochloride monohydrate),
move pH outside 4.3–4.7,
move osmolality or NaCl below the combination of 250–350 mOsm with NaCl > 0.3 wt%,
replace the nonionic polymer/nonionic surfactant pairing,
remove or move the required boric acid + quaternary ammonium halide + chelator framework for claims 3–5.

How broad are the claims for US 6,359,016: what ingredient ranges and selections matter most?

Independent claim 1 is the broadest; claim 2 is narrower via specific excipients; claim 3 is narrower via added antiseptic/borate/chelator components. The “consisting essentially of” language permits some optional components, but constrains inclusion of non-recited core excipient systems that would materially change the formulation’s character relative to the claim’s defined system.

Quantitative claim boundaries (freedom-to-design hotspots)

Element	Claim 1 / 2	Claim 3
Dexamethasone	0.01–0.5 wt%	0.01–0.5 wt%
Ciprofloxacin	0.1–0.4 wt%	0.1–0.4 wt%
Dexamethasone identity	alcohol or acetate	same
Ciprofloxacin identity	HCl monohydrate	same
NaCl	required; >0.3 wt% and tuned to osmolality	same
Osmolality	250–350 mOsm	250–350 mOsm
Nonionic polymer	0.1–0.5 wt%	0.1–0.5 wt%
Nonionic surfactant	0.01–0.2 wt%	0.01–0.2 wt%
Polymer species	claim 2 locks to HEC 0.2%	still required (not re-specified)
Surfactant species	claim 2 locks to tyloxapol 0.05%	still required (not re-specified)
pH	4.5 ± 0.2	4.5 ± 0.2
Boric acid	optional	0.1–1.5 wt% (required)
Quaternary ammonium halide	optional	0.005–0.3 wt% (required)
Chelating agent	optional	0.001–0.1 wt% (required)

“Consisting essentially of” implications (practical)

Claim 1 allows optional preservative/boric acid/pH-adjusting agent/chelating agent. It does not license replacement of the defined nonionic polymer/nonionic surfactant system with an alternative thickener or surfactant class without risking departure from the “essentially of” formulation concept.
Claims 3–5 add required ingredients that will be difficult to remove without leaving the claim.

Which formulations are protected: ophthalmic vs otic vs nasal suspensions under US 6,359,016?

The patent is drafted to cover topically administrable aqueous suspension compositions intended for application to the eye, ear or nose. That breadth matters in two ways:

Jurisdictional scope within the indication class: the claim does not require “ophthalmic” only; “ear or nose” is included, so formulation challenge defenses that argue “this is otic only” are weak if the composition still matches all claim elements.
Regulatory labeling does not alter infringement: infringement is composition-based, not label-based.

Dosage form constraint

The formulation is explicitly an aqueous suspension (not a solution). That can be a design-around target for some competitors, but for dose performance reasons, many marketed combinations remain suspensions.

What specific drug forms (dexamethasone alcohol/acetate; ciprofloxacin HCl monohydrate) change infringement risk?

US 6,359,016 explicitly limits the actives to specific forms:

Dexamethasone is selected from:
- dexamethasone alcohol
- dexamethasone acetate
Ciprofloxacin is:
- ciprofloxacin hydrochloride, monohydrate

Design-around logic typically focuses on one of these form constraints. If a competitor uses a different salt/hydrate (for ciprofloxacin) or a different ester for dexamethasone, it may avoid literal infringement of the claim’s identity limitation, even if concentrations and excipient systems are otherwise similar.

How does pH (4.5 ± 0.2) and osmolality (250–350 mOsm, NaCl > 0.3 wt%) limit the formulation space?

These are among the most enforceable boundaries because they are measurable and not merely ingredient-range variables.

pH boundary (4.3 to 4.7)

The claim requires pH of 4.5 ± 0.2.
Many formulation development teams treat pH as adjustable during manufacturing and stability optimization, which increases the risk of inadvertently crossing back into claimed pH.

Osmolality boundary (250–350 mOsm) + NaCl > 0.3 wt%

Competitors cannot simply use “a bit of salt.” They must hit osmolality while ensuring NaCl exceeds 0.3 wt%.
This creates a two-part constraint: a formulation can meet osmolality but fail the NaCl threshold, or meet NaCl but deviate in osmolality.

Which excipient systems are required: nonionic polymer + nonionic surfactant in US 6,359,016?

Claim 1 excipient categories

Nonionic polymer at 0.1–0.5 wt%
Nonionic surfactant at 0.01–0.2 wt%

Claim 2 locked excipient identities

Nonionic polymer = hydroxyethyl cellulose at 0.2 wt%
Nonionic surfactant = tyloxapol at 0.05 wt%

Claim 3 adds borate/cationic antiseptic/chelator requirements

Quaternary ammonium halide at 0.005–0.3 wt%
Boric acid at 0.1–1.5 wt%
Chelating agent at 0.001–0.1 wt%

This structure is typical of multi-component ophthalmic/otic suspensions where preservative and chelation are tuned for stability and microbial control.

What patent litigation or challenges affect US 6,359,016?

No litigation status, reexamination, reissue, assignment-based enforceability events, or IPR/CBM proceedings are provided in the prompt. Without those facts, no accurate litigation landscape can be constructed.

What is the Orange Book status of US 6,359,016?

No Orange Book listing details (listed drug, application number, patents with expiration details) are provided in the prompt. Without application-level mapping, no Orange Book status can be stated.

When does US 6,359,016 expire and what exclusivity timelines apply?

No filing date, priority date, or term data are provided beyond the patent number itself, and no PTA or exclusivity adjustments can be computed from the prompt. Without the patent’s critical dates and any listed-drug exclusivities, no enforceable US expiration timeline can be generated.

How strong is the patent estate for this formulation family, and where are the infringement vectors?

Based on the claim set structure, infringement risk is highest when a competitor matches:

the specific active forms,
the pH and osmolality + NaCl pair,
the nonionic polymer/nonionic surfactant system, and
for claim 3–5, the boric acid + quaternary ammonium halide + chelator combination and sub-ranges.

Highest-value claim targets

Claim 1 controls broad design space and likely covers many “similar” compositions that keep the same actives and a similar nonionic suspension matrix tuned to the same pH/osmolality.
Claim 2 is a clear “specific formula” fallback that is easier to assess if a competitor uses HEC + tyloxapol at the cited percentages.
Claim 3 is a formulation tightening tool that captures products using quaternary ammonium antiseptics with borate and chelation.
Claims 4–5 provide additional narrowing for frequent antiseptic/chelating pairings, especially benzalkonium chloride + edetate disodium.

What generic entry risks exist for competitors seeking to launch dexamethasone/ciprofloxacin suspensions in the US?

Because the patent is composition-focused and defined tightly by measurable specs, the key generic entry risk is not “label indication.” It is whether the generic can maintain:

actives in the claimed specific forms,
pH within a narrow band,
osmolality within a narrow band tied to NaCl mass fraction, and
the same excipient classes and quantities.

For generics that aim to use the same active pair but change excipient systems or adjust pH/osmolality for stability or tolerability, the risk is that those changes still land inside the claim-defined envelope.

How does US 6,359,016 compare with typical US formulation patents for antibiotic-steroid eye/ear/nose products?

Compared to many formulation patents that recite broader “buffer/tonicity/preservative” language with wide ranges, US 6,359,016 is more enforceable because it ties together multiple independent, measurable formulation parameters:

Narrow pH band
Narrow osmolality band coupled with a NaCl > 0.3% constraint
Specific active forms
Requirement for both nonionic polymer and nonionic surfactant
For claims 3–5, requirement for boric acid plus quaternary ammonium halide plus chelating agent with defined subranges

That combination reduces the “wiggle room” available to a low-effort follow-on formulation.

Key Takeaways

US 6,359,016 protects a specific aqueous suspension formulation for the eye, ear, and nose combining dexamethasone (alcohol/acetate) and ciprofloxacin HCl monohydrate.
Claim 1 is the broadest composition boundary; claim 2 narrows to HEC (0.2%) + tyloxapol (0.05%); claim 3 adds required boric acid (0.1–1.5%), quaternary ammonium halide (0.005–0.3%), and chelator (0.001–0.1%) while keeping the same pH/osmolality constraints.
The most practical infringement/evasion levers are pH, osmolality/NaCl, and the specific active forms; excipient class selections (nonionic polymer and surfactant) and the added ingredients in claims 3–5 are secondary but still high-impact.
The prompt does not provide litigation, Orange Book, or expiration-date inputs, so those parts cannot be stated from the provided information.

FAQs

Does US 6,359,016 cover solutions or only suspensions?
It covers a topically administrable aqueous suspension composition, not an aqueous solution.
Is boric acid required for infringement under claim 1?
No. Under claim 1 it is optional; under claim 3 it becomes required at 0.1–1.5 wt%.
What excipients are uniquely required in claim 2?
Hydroxyethyl cellulose at 0.2 wt% and tyloxapol at 0.05 wt%.
Which antiseptics/chelators are specified in claims 4–5?
Claims 4–5 specify polyquaternium-1 or benzalkonium halides and EDTA salts; claim 5 specifically requires benzalkonium chloride and edetate disodium.
What is the narrowest measurable parameter in these claims?
The pH of 4.5 ± 0.2 and the coupled osmolality of ~250–350 mOsm with NaCl > 0.3 wt%.

References (APA)

United States Patent 6,359,016.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	025661	⤷ Start Trial
Austria	252887	⤷ Start Trial
Australia	7057000	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,359,016

Summary for Patent: 6,359,016